TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00973323
Drug: Xarelto (Rivaroxaban, BAY59-7939)
Normalized name: Xarelto
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg bid
Study: NCT00973323
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-adjusted warfarin based on target INR values
Study: NCT01963845
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04371445
Drug: Dexamethasone Ophthalmic Insert
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care topical ofloxacin eye drop antibiotic regimen.DEXTENZA® is a 3mm long gel-like cylinder that is inserted in the punctum, a natural opening in the lower eyelid. DEXTENZA® is activated by the eye's moisture. DEXTENZA® delivers 0.4 mg dexamethasone, a liquid corticosteroid, onto the surface of the eye automatically for up to 30 days after eye surgery. Dexamethasone is used to reduce inflammation and eye pain. This arm will also receive the standard of care including topical antibiotics.
Study: NCT00334438
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
Study: NCT00265252
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03823703
Drug: Miricorilant
Normalized name: Miricorilant
DrugBank: Miricorilant (DB16234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets taken orally
Study: NCT01754493
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
Study: NCT01578304
Drug: Imidafenacin
Normalized name: imidafenacin
DrugBank: Imidafenacin (DB09262)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Tablet, 12 weeks twice daily
Study: NCT01578304
Drug: Fesoterodine
Normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, 12 weeks once daily
Study: NCT01970878
Drug: GFF MDI (PT 003)
Normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFF MDI administered as two puffs BID
Study: NCT01970878
Drug: FF MDI (PT005)
Normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF MDI administered as two puffs BID
Study: NCT01970878
Drug: Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Study: NCT01386632
Drug: DCA (dichloroacetate)
Normalized name: DCA
DrugBank: Dichloroacetic acid (DB08809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m\^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
Study: NCT00443820
Drug: terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
Study: NCT00443820
Drug: terbinafine
Normalized name: Terbinafine
DrugBank: Terbinafine (DB00857)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
Study: NCT01692210
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
Study: NCT02658734
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
Study: NCT02396017
Drug: Polyethylene Glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bowel purgative
Study: NCT00709605
Drug: VRC-HIVADV014-00-VP
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02771366
Drug: Fermented Papaya Preparation
Normalized name: Carica papaya preparation
DrugBank: Papaya (DB10658)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
Study: NCT00671853
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
Study: NCT00671853
Drug: Placebo for quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
Study: NCT01577849
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Vitamin D3 24,000 IU
Study: NCT01577849
Drug: DP-R206
Normalized name: DP-303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
Study: NCT04036305
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be injected subcutaneously with a single 0.5ml dose
Study: NCT01257464
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg po one dose
Study: NCT01645826
Drug: Diltiazem Hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
Study: NCT01645826
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
Study: NCT03749447
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl capsules
Study: NCT03943589
Drug: Imlifidase
Normalized name: Imlifidase
DrugBank: Imlifidase (DB15258)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: All subjects will receive imlifidase (Day 1) prior to standard care IVIg
Study: NCT00027924
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027924
Drug: cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00027924
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00204984
Drug: oral hydralazine and intravenous nesiritide
Normalized name: nesiritide
DrugBank: Hydralazine (DB01275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vasodilators
Study: NCT06072222
Drug: Meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: all patients in both groups receive meropenam and put on the ventilators for 2 weeks
Study: NCT03662074
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01889173
Drug: Cyclobenzaprine tablets
Normalized name: cyclobenzaprine Oral Tablet
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
Study: NCT03610464
Drug: Amphetamine Extended Release Suspension [Dyanavel]
Normalized name: amphetamine Extended Release Suspension [Dyanavel]
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of study drug (AMPH EROS, 2.5 mg/mL), pharmacokinetic analysis
Study: NCT00489710
Drug: talabostat mesylate
Normalized name: mesylate
DrugBank: Talabostat (DB06182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01059643
Drug: pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6 milligrams (mg), administered subcutaneously approximately 24 hours after third dose of LY2523355 on Day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
Study: NCT00431184
Drug: Pentazocine
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arms description
Study: NCT00431184
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arms description
Study: NCT03185143
Drug: Sumatriptan 100 mg
Normalized name: sumatriptan 100 MG
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
Study: NCT02151084
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02151084
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02151084
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00653185
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study: NCT00653185
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study: NCT00653185
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study: NCT00653185
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
Study: NCT00246337
Drug: Rizatriptan
Normalized name: Rizatriptan
DrugBank: Rizatriptan (DB00953)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rizatriptan 10 mg; one orally-administered dose
Study: NCT00494533
Drug: Remodulin (treprostinil sodium)
Normalized name: treprostinil Injectable Solution [Remodulin]
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00403650
Drug: Iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
Study: NCT03640481
Drug: Belumosudil (KD025)
Normalized name: belumosudil
DrugBank: Belumosudil (DB16703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study: NCT01226511
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00444743
Drug: MM-093
Normalized name: MM-093
DrugBank: MM-093 (DB05512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg, administered subcutaneously, weekly
Study: NCT04082598
Drug: Amoxicillin Clavulanate
Normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tooth extractions are performed for all groups and antibiotics prescribed according to the allocation to the different arms
Study: NCT01686152
Drug: Imiquimod Cream, 3.75%
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03593421
Drug: synthetic PreImplantation Factor
Normalized name: Synthetic PreImplantation Factor
DrugBank: Preimplantation factor (DB16301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: peptide
Study: NCT03285503
Drug: Aripiprazole IM Depot
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
Study: NCT02174913
Drug: Target controlled infusion of propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCI propofol (3-7 mcg/dL, Schnider model) is used for total intravenous anesthesia in both groups
Study: NCT02174913
Drug: Atracurium
Normalized name: Atracurium
DrugBank: Atracurium besylate (DB00732)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atracurium 0.6 mg/kg is used for endotracheal intubation
Study: NCT00332852
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg/day - oraly
Study: NCT00439218
Drug: sodium phenylbutyrate
Normalized name: Sodium Phenylbutyrate
DrugBank: Phenylbutyric acid (DB06819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
Study: NCT00435435
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01105702
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01105702
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01105702
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005625
Drug: trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03063021
Drug: N-Acetyl Cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets of N-acetyl-cysteine
Study: NCT00010959
Drug: Cimicifuga racemosa
Normalized name: CIMICIFUGA RACEMOSA ROOT
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00010959
Drug: Trifolium pratense
Normalized name: TRIFOLIUM PRATENSE LEAF
DrugBank: Trifolium pratense pollen (DB15530)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01428583
Drug: oxycodone HCl and naltrexone HCl extended-release capsules
Normalized name: naltrexone hydrochloride / oxycodone hydrochloride Extended Release Oral Capsule
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
Study: NCT01765855
Drug: Betrixaban single oral dose
Normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02546791
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000207
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02612480
Drug: ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
Study: NCT02612480
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
Study: NCT06021756
Drug: Intervention: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine will be administered as intravenous infusions with infusion rates ranging from 0.05 mg/kg/hr to 0.30 mg/kg/hr.
Study: NCT00215371
Drug: Formoterol Fumarate
Normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03262740
Drug: BMS-986195
Normalized name: BMS-986195
DrugBank: Branebrutinib (DB15347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of specified dose on specified days
Study: NCT03262740
Drug: Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Contraceptive
Study: NCT00286117
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00286117
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00638456
Drug: Budesonide plus Prevacid
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
Study: NCT03945084
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib will be administered as a flat-fixed, continuous daily dose:~≥77 kg and ≥150,000 µL: 300 mg (3 X 100 mg capsules) daily \<77 kg or \<150,000 µL: 200 mg (2 X 100 mg capsules) daily\*~\* For patients whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily will be permitted if no treatment interruption or discontinuation will be required during the first 2 cycles of therapy
Study: NCT02319707
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study group: divided into two groups:~• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.~• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor.
Study: NCT02319707
Drug: Oxytocin in 100 ml NaCl 0.9%
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The control group:~pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department).
Study: NCT01962402
Drug: lorcaserin
Normalized name: Lorcaserin
DrugBank: Lorcaserin (DB04871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
Study: NCT00673088
Drug: Ropinirole Hydrochloride
Normalized name: Ropinirole Hydrochloride
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Restless Leg Syndrome
Study: NCT03316170
Drug: NRT Sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail.
Study: NCT05085106
Drug: Felbinac trometamol eye drop
Normalized name: felbinac
DrugBank: Felbinac (DB07477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felbinac trometamol eye drop: 0.025%、0.05%、0.1%、0.2%、0.3%, 1 drop will be instilled as instructed over one day in single-dose study; 0.1%, 0.2%, 1 drop per time, four times each day and for seven days totally in multiple-dose study.
Study: NCT04874142
Drug: YYC506-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single administration
Study: NCT04874142
Drug: YYC506-T + YYC506-A
Normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: concomotant administration
Study: NCT04874142
Drug: YYC506-A + YYC506-T
Normalized name: (T,G)-A-L
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: concomotant administration
Study: NCT04601103
Drug: High SLS toothpaste
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More than or equal to X ppm Sodium Lauryl Sulfate
Study: NCT00578344
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
Study: NCT02165202
Drug: Rilpivirine
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
Study: NCT00188812
Drug: donepezil hcl
Normalized name: donepezil HCl
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no